$RPRX
Royalty Pharma plc

2024 Q3 Form 10-Q Financial Statement

#000180276824000058 Filed on November 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q3
Revenue $564.7M
YoY Change 5.29%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $56.72M
YoY Change -0.84%
% of Gross Profit
Research & Development $500.0K
YoY Change -99.01%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $500.0K
YoY Change -99.01%
Operating Profit $735.1M
YoY Change 385.38%
Interest Expense $72.94M
YoY Change 58.45%
% of Operating Profit 9.92%
Other Income/Expense, Net $71.28M
YoY Change -342.75%
Pretax Income $806.4M
YoY Change 560.53%
Income Tax $0.00
% Of Pretax Income 0.0%
Net Earnings $544.0M
YoY Change 654.34%
Net Earnings / Revenue 96.33%
Basic Earnings Per Share $1.22
Diluted Earnings Per Share $1.21
COMMON SHARES
Basic Shares Outstanding 447.6M shares
Diluted Shares Outstanding 592.7M shares

Balance Sheet

Concept 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $998.6M
YoY Change 6.03%
Cash & Equivalents $950.1M
Short-Term Investments $48.50M
Other Short-Term Assets $4.969M
YoY Change -26.75%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.794B
YoY Change 3.79%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $351.0M
YoY Change -7.21%
Other Assets $42.79M
YoY Change 111.7%
Total Long-Term Assets $16.25B
YoY Change 15.01%
TOTAL ASSETS
Total Short-Term Assets $1.794B
Total Long-Term Assets $16.25B
Total Assets $18.04B
YoY Change 13.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $22.06M
YoY Change 57.54%
Accrued Expenses $38.41M
YoY Change 195.48%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $996.9M
YoY Change
Total Short-Term Liabilities $1.168B
YoY Change 812.79%
LONG-TERM LIABILITIES
Long-Term Debt $6.610B
YoY Change 7.82%
Other Long-Term Liabilities $5.580M
YoY Change -49.27%
Total Long-Term Liabilities $6.616B
YoY Change 7.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.168B
Total Long-Term Liabilities $6.616B
Total Liabilities $7.784B
YoY Change 24.13%
SHAREHOLDERS EQUITY
Retained Earnings $2.765B
YoY Change 29.51%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $2.657M
YoY Change 1.26%
Treasury Stock Shares
Shareholders Equity $6.870B
YoY Change
Total Liabilities & Shareholders Equity $18.04B
YoY Change 13.79%

Cashflow Statement

Concept 2024 Q3
OPERATING ACTIVITIES
Net Income $544.0M
YoY Change 654.34%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities $703.6M
YoY Change 22.69%
INVESTING ACTIVITIES
Capital Expenditures $1.195B
YoY Change 164.81%
Acquisitions
YoY Change
Other Investing Activities $1.870M
YoY Change 274.0%
Cash From Investing Activities -$1.193B
YoY Change 164.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -325.5M
YoY Change -76.06%
NET CHANGE
Cash From Operating Activities 703.6M
Cash From Investing Activities -1.193B
Cash From Financing Activities -325.5M
Net Change In Cash -814.6M
YoY Change -34.13%
FREE CASH FLOW
Cash From Operating Activities $703.6M
Capital Expenditures $1.195B
Free Cash Flow -$491.0M
YoY Change -501.11%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001802768
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
Royalty Pharma plc
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
X0
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1535773
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Document Type
DocumentType
10-Q
dei Entity File Number
EntityFileNumber
001-39329
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
595683000 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.43
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
449085000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
448162000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
601138000 shares
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
6135285000 usd
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6135285000 usd
us-gaap Profit Loss
ProfitLoss
982502000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3263000 usd
rprx Increase Decrease In Cash Collections On Financing Receivables
IncreaseDecreaseInCashCollectionsOnFinancingReceivables
2205933000 usd
rprx Increase Decrease In Cash Collections On Financing Receivables
IncreaseDecreaseInCashCollectionsOnFinancingReceivables
2454054000 usd
CY2024Q3 us-gaap Assets
Assets
18042242000 usd
CY2023Q4 us-gaap Assets
Assets
16381851000 usd
CY2024Q3 rprx Distributions Payable To Legacy Non Controlling Interests Current
DistributionsPayableToLegacyNonControllingInterestsCurrent
79149000 usd
CY2023Q4 rprx Distributions Payable To Legacy Non Controlling Interests Current
DistributionsPayableToLegacyNonControllingInterestsCurrent
83155000 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
22055000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
15165000 usd
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10022
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
883-0200
dei Security12b Title
Security12bTitle
Class A ordinary shares, par value $0.0001
dei Trading Symbol
TradingSymbol
RPRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
950052000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
18300000 usd
CY2024Q3 rprx Other Royalty Income Receivable Current
OtherRoyaltyIncomeReceivableCurrent
24901000 usd
CY2024Q3 rprx Deferred Shares Shares Outstanding
DeferredSharesSharesOutstanding
390502000 shares
CY2024Q3 rprx Deferred Shares Shares Issued
DeferredSharesSharesIssued
390502000 shares
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
477010000 usd
CY2024Q3 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
765773000 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
51682000 usd
dei Entity Address Address Line1
EntityAddressAddressLine1
110 East 59th Street
CY2024Q3 us-gaap Interest Payable Current
InterestPayableCurrent
38412000 usd
CY2024Q3 us-gaap Revenues
Revenues
564690000 usd
CY2023Q3 us-gaap Revenues
Revenues
536313000 usd
CY2023Q3 us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
277137000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
500000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50500000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
56720000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
48500000 usd
CY2023Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
14088655000 usd
CY2024Q3 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
228867000 usd
CY2023Q4 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
199487000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
657300000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
437100000 usd
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
-170384000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
384871000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
735074000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
151442000 usd
CY2024Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
10407000 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
66506000 usd
CY2024Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
3000000 usd
CY2023Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-8680000 usd
CY2024Q3 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
50849000 usd
CY2023Q3 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
1541000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
57234000 usd
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-5222000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
57680000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
7300000 usd
CY2024Q3 us-gaap Interest Income Other
InterestIncomeOther
17508000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1654000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1707000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
71284000 usd
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
592726000 shares
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
23436000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
806358000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
122077000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
262371000 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
49963000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
543987000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
72114000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.22
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.16
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.21
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.16
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
447628000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
448439000 shares
CY2024Q3 rprx Financing Receivable Allowance For Credit Loss Changes In Expected Cash Flows
FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
3423584000 usd
CY2024Q3 rprx Financing Receivables After Allowance For Credit Loss Changes In Expected Cash Flows
FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
15935508000 usd
CY2024Q3 rprx Financing Receivable Allowance For Credit Loss Cumulative Adjustment And Credit Loss Expense Reversal
FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal
201661000 usd
CY2024Q3 us-gaap Notes Receivable Net
NotesReceivableNet
15733847000 usd
CY2023Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
738438000 usd
CY2023Q4 rprx Other Royalty Income Receivable Current
OtherRoyaltyIncomeReceivableCurrent
22405000 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
4969000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
18040000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
1794195000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1274193000 usd
CY2024Q3 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
14968074000 usd
CY2024Q3 us-gaap Equity Method Investments
EquityMethodInvestments
351017000 usd
CY2023Q4 us-gaap Equity Method Investments
EquityMethodInvestments
375894000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
42789000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6522000 usd
CY2024Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
996942000 usd
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 usd
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
31200000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
11375000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1167758000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
161377000 usd
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6610437000 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6135285000 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5580000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
900000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
7783775000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
6297562000 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 rprx Deferred Shares Par Or Stated Value Per Share
DeferredSharesParOrStatedValuePerShare
0.000001
CY2023Q4 rprx Deferred Shares Par Or Stated Value Per Share
DeferredSharesParOrStatedValuePerShare
0.000001
CY2023Q4 rprx Deferred Shares Shares Issued
DeferredSharesSharesIssued
384640000 shares
CY2023Q4 rprx Deferred Shares Shares Outstanding
DeferredSharesSharesOutstanding
384640000 shares
CY2024Q3 rprx Deferred Shares Value Issued
DeferredSharesValueIssued
0 usd
CY2023Q4 rprx Deferred Shares Value Issued
DeferredSharesValueIssued
0 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4107742000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4011435000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2764685000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2517583000 usd
CY2024Q3 us-gaap Minority Interest
MinorityInterest
3388589000 usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
3557792000 usd
CY2024Q3 us-gaap Treasury Stock Value
TreasuryStockValue
2657000 usd
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
2629000 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10258467000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10084289000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18042242000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16381851000 usd
us-gaap Revenues
Revenues
1669935000 usd
us-gaap Revenues
Revenues
1758486000 usd
CY2024Q3 us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
-227604000 usd
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
568425000 usd
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
637169000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1500000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51500000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
169080000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
190563000 usd
us-gaap Costs And Expenses
CostsAndExpenses
739005000 usd
us-gaap Costs And Expenses
CostsAndExpenses
879232000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
930930000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
879254000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2039000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
28614000 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
46033000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
159751000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
139932000 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
3000000 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-2290000 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
81455000 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
31994000 usd
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
103900000 usd
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
122500000 usd
us-gaap Interest Income Other
InterestIncomeOther
38306000 usd
us-gaap Interest Income Other
InterestIncomeOther
65791000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
661000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3429000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-29365000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
65532000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
103248000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
996462000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
982502000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
806358000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
122077000 usd
us-gaap Profit Loss
ProfitLoss
996462000 usd
us-gaap Profit Loss
ProfitLoss
982502000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
345693000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
342008000 usd
us-gaap Net Income Loss
NetIncomeLoss
650769000 usd
us-gaap Net Income Loss
NetIncomeLoss
640494000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.45
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
604717000 shares
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9751818000 usd
CY2024Q3 rprx Noncontrolling Interest Increase From Contributions
NoncontrollingInterestIncreaseFromContributions
2245000 usd
CY2024Q3 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
113182000 usd
CY2024Q3 us-gaap Dividends Cash
DividendsCash
94061000 usd
CY2024Q3 us-gaap Stockholders Equity Other
StockholdersEquityOther
0 usd
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
525000 usd
CY2024Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
95236000 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
806358000 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10258467000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9813686000 usd
CY2023Q3 rprx Noncontrolling Interest Increase From Contributions
NoncontrollingInterestIncreaseFromContributions
2850000 usd
CY2023Q3 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
120198000 usd
CY2023Q3 us-gaap Dividends Cash
DividendsCash
89751000 usd
CY2023Q3 us-gaap Stockholders Equity Other
StockholdersEquityOther
0 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
581000 usd
CY2023Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
144148000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
122077000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9585097000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10084289000 usd
rprx Noncontrolling Interest Increase From Contributions
NoncontrollingInterestIncreaseFromContributions
6797000 usd
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
367320000 usd
us-gaap Dividends Cash
DividendsCash
282809000 usd
us-gaap Stockholders Equity Other
StockholdersEquityOther
0 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1819000 usd
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
179663000 usd
us-gaap Profit Loss
ProfitLoss
996462000 usd
us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
1108000 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10258467000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9525373000 usd
rprx Noncontrolling Interest Increase From Contributions
NoncontrollingInterestIncreaseFromContributions
9690000 usd
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
386590000 usd
us-gaap Dividends Cash
DividendsCash
268989000 usd
us-gaap Stockholders Equity Other
StockholdersEquityOther
0 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1740000 usd
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
278629000 usd
us-gaap Profit Loss
ProfitLoss
982502000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9585097000 usd
rprx Proceeds From Cash Collections From Royalties Received On Financing Receivables
ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables
2205933000 usd
rprx Proceeds From Cash Collections From Royalties Received On Financing Receivables
ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables
2454054000 usd
rprx Proceeds From Cash Collections From Royalties Received On Intangible Assets
ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets
14420000 usd
rprx Proceeds From Cash Collections From Royalties Received On Intangible Assets
ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets
1067000 usd
rprx Proceeds From Cash Collections From Other Royalties Received On Financing Receivables
ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables
79334000 usd
rprx Proceeds From Cash Collections From Other Royalties Received On Financing Receivables
ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables
84275000 usd
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
13396000 usd
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
18823000 usd
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
37447000 usd
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
63135000 usd
rprx Payments For Ongoing Development Stage Funding
PaymentsForOngoingDevelopmentStageFunding
1500000 usd
rprx Payments For Ongoing Development Stage Funding
PaymentsForOngoingDevelopmentStageFunding
1500000 usd
rprx Payments For Upfront Development Stage Funding
PaymentsForUpfrontDevelopmentStageFunding
0 usd
rprx Payments For Upfront Development Stage Funding
PaymentsForUpfrontDevelopmentStageFunding
50000000 usd
rprx Payments For Operating Costs And Professional Services
PaymentsForOperatingCostsAndProfessionalServices
163804000 usd
rprx Payments For Operating Costs And Professional Services
PaymentsForOperatingCostsAndProfessionalServices
188839000 usd
us-gaap Interest Paid Net
InterestPaidNet
158765000 usd
us-gaap Interest Paid Net
InterestPaidNet
165841000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2026461000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2215174000 usd
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
20397000 usd
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
39225000 usd
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
10955000 usd
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
10550000 usd
rprx Payments To Acquire Equity Securities Fnni
PaymentsToAcquireEquitySecuritiesFNNI
62500000 usd
rprx Payments To Acquire Equity Securities Fnni
PaymentsToAcquireEquitySecuritiesFNNI
0 usd
rprx Proceeds From Issuance Of Equity Securities Fnni
ProceedsFromIssuanceOfEquitySecuritiesFNNI
98575000 usd
rprx Proceeds From Issuance Of Equity Securities Fnni
ProceedsFromIssuanceOfEquitySecuritiesFNNI
0 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
150000000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
7200000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
24391000 usd
us-gaap Payments To Acquire Finance Receivables
PaymentsToAcquireFinanceReceivables
2009283000 usd
us-gaap Payments To Acquire Finance Receivables
PaymentsToAcquireFinanceReceivables
1113283000 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
18000000 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
0 usd
rprx Payments For Milestones
PaymentsForMilestones
50000000 usd
rprx Payments For Milestones
PaymentsForMilestones
12400000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-2039000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2172527000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1072617000 usd
rprx Payments To Noncontrolling Interests Portfolio Receipts
PaymentsToNoncontrollingInterestsPortfolioReceipts
281078000 usd
rprx Payments To Noncontrolling Interests Portfolio Receipts
PaymentsToNoncontrollingInterestsPortfolioReceipts
284637000 usd
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
93711000 usd
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
95045000 usd
rprx Payment Of Dividends To Shareholders
PaymentOfDividendsToShareholders
282809000 usd
rprx Payment Of Dividends To Shareholders
PaymentOfDividendsToShareholders
268989000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
177044000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
274559000 usd
rprx Proceeds From Noncontrolling Interests Research And Development
ProceedsFromNoncontrollingInterestsResearchAndDevelopment
527000 usd
rprx Proceeds From Noncontrolling Interests Research And Development
ProceedsFromNoncontrollingInterestsResearchAndDevelopment
455000 usd
rprx Proceeds From Noncontrolling Interests Other
ProceedsFromNoncontrollingInterestsOther
3329000 usd
rprx Proceeds From Noncontrolling Interests Other
ProceedsFromNoncontrollingInterestsOther
5915000 usd
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
0 usd
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
1000000000 usd
us-gaap Proceeds From Issuance Of Other Long Term Debt
ProceedsFromIssuanceOfOtherLongTermDebt
1471235000 usd
us-gaap Proceeds From Issuance Of Other Long Term Debt
ProceedsFromIssuanceOfOtherLongTermDebt
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
12316000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-9025000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
619108000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1916860000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
473042000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-774303000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
477010000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1710751000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
950052000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
936448000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates. The results for the interim periods are not necessarily indicative of results for the full year.</span></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to the current period presentation.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, available for sale debt securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents balances as of September 30, 2024 and December 31, 2023 were held with Bank of America, State Street, TD Bank, Citibank, U.S. Bank, DNB Bank and Scotiabank. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, GSK, Roche, Johnson &amp; Johnson, Biogen, AbbVie, Astellas, Pfizer, Novartis and Gilead. As of September 30, 2024 and December 31, 2023, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for 33% and 32% of our current portion of financial royalty assets, respectively, and represented the largest individual marketer and payor of our royalties.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant credit losses with respect to the collection of income or revenues on our royalty assets.</span></div>
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
500254000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
200946000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
701200000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
48500000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
657300000 usd
CY2024Q3 rprx Financial Liabilities Fair Value Disclosure Non Current
FinancialLiabilitiesFairValueDisclosureNonCurrent
4600000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
701200000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
352367000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
102133000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
454500000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
18300000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
437100000 usd
CY2023Q4 rprx Financial Liabilities Fair Value Disclosure Non Current
FinancialLiabilitiesFairValueDisclosureNonCurrent
900000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
454500000 usd
CY2024Q3 us-gaap Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
50800000 usd
us-gaap Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
33300000 usd
CY2023Q3 us-gaap Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
4700000 usd
us-gaap Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
14400000 usd
CY2024Q3 us-gaap Notes Receivable Gross
NotesReceivableGross
19359092000 usd
CY2024Q3 us-gaap Notes Receivable Net
NotesReceivableNet
15700000000 usd
CY2023Q4 us-gaap Notes Receivable Gross
NotesReceivableGross
17892238000 usd
CY2023Q4 rprx Financing Receivable Allowance For Credit Loss Changes In Expected Cash Flows
FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
2927438000 usd
CY2023Q4 rprx Financing Receivables After Allowance For Credit Loss Changes In Expected Cash Flows
FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
14964800000 usd
CY2023Q4 rprx Financing Receivable Allowance For Credit Loss Cumulative Adjustment And Credit Loss Expense Reversal
FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal
137707000 usd
CY2023Q4 us-gaap Notes Receivable Net
NotesReceivableNet
14827093000 usd
CY2023Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
3065145000 usd
rprx Financing Receivable Change In Present Value Increases To Cumulative Allowance
FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowance
1083352000 usd
rprx Financing Receivable Change In Present Value Decreases To Cumulative Allowance Reversal Of Expense
FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense
578881000 usd
rprx Financing Receivable Change In Present Value Write Off Cumulative Allowance
FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance
8325000 usd
us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
-63954000 usd
CY2024Q3 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
3625245000 usd
CY2023Q4 rprx Financing Receivable Allowance For Credit Loss Cumulative Adjustment And Credit Loss Expense Reversal
FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal
137700000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
500000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1500000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50500000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51500000 usd
CY2024Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
192621000 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
164715000 usd
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
7607379000 usd
CY2024Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
996942000 usd
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6610437000 usd
CY2024Q3 rprx Number Of Classes Of Voting Stock
NumberOfClassesOfVotingStock
2 class
CY2024Q3 rprx Common Stock Voting Rights Number Of Votes
CommonStockVotingRightsNumberOfVotes
1 vote
CY2024Q3 rprx Common Stock Quarterly Conversion Basis
CommonStockQuarterlyConversionBasis
1
CY2023 rprx Purchase Of Non Controlling Interest
PurchaseOfNonControllingInterest
11400000 usd
rprx Purchase Of Non Controlling Interest
PurchaseOfNonControllingInterest
12500000 usd
rprx Share Based Compensation Arrangement By Share Based Payment Award Covenant Percentage Of Net Economic Profit
ShareBasedCompensationArrangementByShareBasedPaymentAwardCovenantPercentageOfNetEconomicProfit
0.20
rprx Number Of Quarterly Cash Dividends
NumberOfQuarterlyCashDividends
3 quarterly_dividend
CY2024Q2 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.21
CY2024Q1 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.21
CY2024Q3 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.21
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
282800000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
P1Y
CY2024Q3 us-gaap Profit Loss
ProfitLoss
806358000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
122077000 usd
us-gaap Profit Loss
ProfitLoss
996462000 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
543987000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
72114000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
650769000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
640494000 usd
CY2024Q3 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
175399000 usd
CY2023Q3 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
24055000 usd
us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
209844000 usd
us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
225361000 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
719386000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
96169000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
860613000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
865855000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
447628000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
448439000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
449085000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
448162000 shares
CY2024Q3 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
145085000 shares
CY2023Q3 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
152691000 shares
us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
146576000 shares
us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
156541000 shares
CY2024Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
13000 shares
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
8000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
22000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
14000 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
592726000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
601138000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
595683000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
604717000 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.22
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.43
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.21
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.43
us-gaap Profit Loss
ProfitLoss
996462000 usd
us-gaap Profit Loss
ProfitLoss
982502000 usd
rprx Increase Decrease In Financial Royalty Assets
IncreaseDecreaseInFinancialRoyaltyAssets
1587577000 usd
rprx Increase Decrease In Financial Royalty Assets
IncreaseDecreaseInFinancialRoyaltyAssets
1674689000 usd
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
568425000 usd
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
637169000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
14256000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
15658000 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
3000000 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-2290000 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
81455000 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
31994000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2039000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
28614000 usd
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
13396000 usd
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
18823000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1819000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1740000 usd
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
103900000 usd
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
122500000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1801000 usd
rprx Increase Decrease In Other Royalty Income Receivable
IncreaseDecreaseInOtherRoyaltyIncomeReceivable
2496000 usd
rprx Increase Decrease In Other Royalty Income Receivable
IncreaseDecreaseInOtherRoyaltyIncomeReceivable
669000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-13068000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
1942000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3582000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1650000 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-13270000 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-41567000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
980000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2026461000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2215174000 usd
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001802768-24-000058-index-headers.html Edgar Link pending
0001802768-24-000058-index.html Edgar Link pending
0001802768-24-000058.txt Edgar Link pending
0001802768-24-000058-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rprx-20240930.htm Edgar Link pending
rprx-20240930.xsd Edgar Link pending
rprx-20240930ex311.htm Edgar Link pending
rprx-20240930ex312.htm Edgar Link pending
rprx-20240930ex32.htm Edgar Link pending
Show.js Edgar Link pending
rprx-20240930_cal.xml Edgar Link unprocessable
rprx-20240930_def.xml Edgar Link unprocessable
rprx-20240930_lab.xml Edgar Link unprocessable
rprx-20240930_pre.xml Edgar Link unprocessable
rprx-20240930_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable